Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy

HIV Clinical Trials

Volumn 7, Issue 6, 2006, Pages 291-308

  Sprinz, Eduardo ^a   Neto, J Andrade ^b   Bargman, Eduardo ^c   Green, Stephen L ^d   Luo, Michelle P ^e   Sylte, Jacquelyn R ^e   McMillan, Florence I ^e   King, Kathryn R ^e   Rode, Richard A ^e   Brun, Scott C ^e   Hanna, George J ^e   Podsadecki, Thomas J ^e  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^c Hospital Bernardino Rivadavia   (Argentina)

^d Hampton Roads Medical Specialists   (United States)

^e ABBOTT LABORATORIES   (United States)

Author keywords

HAART; Iopinavir; Quality of life

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ANAPHYLAXIS; ANTIVIRAL ACTIVITY; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG FATALITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; KIDNEY COLIC; MALE; MEMORY DISORDER; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEPHROLITHIASIS; NIGHTMARE; OUTCOME ASSESSMENT; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UNPLEASANT DREAM; VIRUS INFECTION; VIRUS LOAD;

EID: 33846490815     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0706-291     Document Type: Article

References (38)

1. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. May 4, 2006. Available at: http://aidsinfo.nih.gov/guidelines. Accessed May 2006.
2. Treatment for adult HIV infection. 2004 recommendations of the International AIDS Society - USA Panel. JAMA. 2004;292:251-265.
3. British HIV Association (BHIVA). Guidelines for the treatment of HIV disease with antiretroviral therapy. Update 2005. Available at: http://bhiva.org/
4. French treatment guidelines. Prise en charge thérapeutique des personnes infectées par le VIH, recommendations du groupe d'experts. Misistére de l'emploi et de la solidarité. 2004. Available at: http://lesrapports.ladocumentationfracaise.fr/
5. Palella F, Delaney K, Moorman A et al. Declining morbidity and mortality among subjects with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338:853-860.
6. Schiller DS. Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy. Am J Health Syst Pharm. 2004;61 (23):2507-2522.
7. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 2001;358:1322-1327.
8. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445-449.
9. O'Brien ME, Clark RA, Besch CL, et al. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34:407-414.
10. Vincent E, Bouhnik AD, Carrieri MP, et al. MANIF-2000 Study Group. Impact of HAART-related side effects on unsafe sexual behaviours in HIV-infected injecting drug users: 7-year follow up. AIDS. 2004;18:1321-1325.
11. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs. 2000;59:581-620.
12. 3. Am J Gastroenterol. 2000;95:3142-3146.
13. Tramarin A, Parise N, Campostrini S, et al. Palladio Study Group. Association between diarrhoea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Qual Life Res. 2004;13:243-250.
14. Sherman DS, Fish DN. Management of protease inhibitor-associated diarrhea. Clin Infect Dis. 2000;30:908-914.
15. Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in human immunodeficiency virus-infected patients: a review. Am J Med. 1999;107:78-84.
16. Valente SM. Depression and HIV disease. J Assoc Nurses AIDS Care. 2003;14:41-51.
17. Morrison MF, Petitto JM, Ten Have T, et al. Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry. 2002;159:789-796.
18. Bouhnik AD, Preau M, Vincent E, et al., MANIF 2000 Study Group. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther. 2005;10:53-61.
19. Bertz R, Lam W, Brun S, et al. Multiple-dose pharmacokinetics (PK) of LPV/ritonavir (LPV/r) in HIV+ subjects. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, California. Abstract 0327.
20. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:350-359.
21. Gulick RM, da Silva B, McMillan F, et al. Lopinavir/ritonavir (LPV/ r)-based therapy in antiretroviral-naïve, HIV-infected patients: 6-year follow-up of Study 720. In: Program and abstracts of the 7th International Congress on Drug Therapy in HIV Infection; November 14-18, 2004; Glasgow, UK. Abstract P28.
22. King M, Brun S, Tschampa J, et al. Relationship between adherence and the developments of viral resistance in antiretroviral-naïve patients treated with lopinavir/ritonavir (LPV/r) or nelfinavir (NFV). In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment;. July 13-16, 2003; Paris, France. Abstract 798.
23. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.
24. Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS. 2004;18:775-779.
25. Friend J, Parkin N, Liegler T, et al. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS. 2004;18:1965-1966.
26. Conradie F, Sanne I, Venter W, et al. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS. 2004; 18:1084-1085.
27. http://rcc.tech-res.com/DAIDS%20RCC%20Forms/ TB_ToxicityTables_Adult_TRP_v01a.pdf
28. Justice AC, Holmes W, Gifford AL, et al. Adult AIDS Clinical Trials Unit Outcomes Committee. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(suppl 1):S77-90.
29. Pignone MP, Gaynes BN, Rushton JL, et al. Screening for depression in adults: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;136:765-776.
30. Wu AW, Revicki DA, Jacobson D, et al. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Survey (MOS-HIV). Qual Life Res. 1997;6:481-493.
31. Kohout FJ, Berkman LF, Evans DA. Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) depression symptoms index. J Aging Health. 1993;5:179-193.
32. Mantel N. Assessing laboratory evidence for neoplastic activity. Biometrics. 1980;36:381-399.
33. Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics. 1985;41:295-301.
34. Sloan JA, Cella D, Hays RD. Clinial significance of patient-reported questionnaire data: another step toward concensus. J Clin Epidem. 2005;58:1217-1219.
35. Israelski DM, Shen Y, Traves M, Sylte J, Tressler R, Rode R. Gender, ethnic, and geographic associations with quality of life (QOL) in patients before and after PI/NNRTI substitution with lopinavir/ ritonavir. In: 9th European AIDS Conference; October 26-29, 2003; Warsaw, Poland.
36. Andrade-Neto J, Soto A, Sprinz E. Improved tolerability and quality of life in subjects receiving lopinavir/ritonavir. In: 6th International Conference on Drug Therapy in HIV Infection; November 2002; Glasgow, UK.
37. Rode R, DaSilva B, Bortolozzi R, et al. Improved quality of life (QOL) in HCV co-infected subjects substituting their protease inhibitor or non-nucleoside reverse transcriptase inhibitor for lopinavir/ritonavir (LPV/r) soft gelatin capsules. In: Program and abstracts of the 2nd International Workshop on HIV and Hepatitis Co-infection; January 12-14, 2006; Amsterdam, The Netherlands. Poster 19.
38. Murphy RL, Smith WJ. Switch studies: a review. HIV Med. 2002;3:146-155.